Regeneron Pharmaceuticals Inc. (REGN) Trading Volume Drops 48.37% to $635 Million, Ranks 132nd

On March 24, 2025, Regeneron Pharmaceuticals Inc. (REGN) saw a trading volume of $635 million, marking a 48.37% decrease from the previous day. This placed the company at the 132nd position in terms of trading volume for the day. The stock price of Regeneron Pharmaceuticals Inc. (REGN) rose by 0.38%.

On February 20, Morgan Stanley analyst Ronald Kamdem maintained a Buy rating for Regeneron Pharmaceuticals Inc. (REGN). This endorsement from a prominent analyst could potentially influence investor sentiment and contribute to the stock's performance.

Regeneron Pharmaceuticals Inc. (REGN) is listed on the S&P 500 index, which is a significant benchmark for the U.S. stock market. This inclusion indicates the company's prominence and stability within the healthcare and biotechnology sectors.

Regeneron Pharmaceuticals Inc. (REGN) is also a component of the Vanguard S&P 500 ETF (VOO), holding a 0.15% weight in the fund. This inclusion in a widely followed ETF further underscores the company's importance in the market and its potential impact on investor portfolios.